Press Releases

  • May. 16, 2017 biOasis Announces the Engagement of Mackie Research to Provide Market Making Services

    VANCOUVER, British Columbia–(Business Wire)– Bioasis Technologies, Inc. (OTCQB:BIOAF; TSX.V:BTI) (the “Company”), is pleased to announce that, subject to regulatory approval, it has retained Mackie Research Capital Corporation (“Mackie Research”) to initiate its market making service to provide market making services to the Company in compliance with the policies and guidelines of the TSX Venture Exchange… Read more »

  • Apr. 24, 2017 BIOASIS ANNOUNCES GRANT OF STOCK OPTIONS AND RESTRICTED STOCK UNITS

    VANCOUVER, British Columbia–(Business Wire)– Bioasis Technologies, Inc. (OTCQB:BIOAF; TSX.V:BTI) (the “Company”) is pleased to announce that pursuant to the terms of its stock option plan (the “Option Plan”) and restricted stock units plan (the “RSU Plan”), the Company has granted a total of 2,377,478 stock options and 225,000 Restricted Share Units (RSUs) to its officers,… Read more »

  • biOasis Announces Investor Relations Service Agreement

    VANCOUVER, British Columbia–(Business Wire)– Bioasis Technologies, Inc. (OTCQB:BIOAF; TSX.V:BTI) (the “Company”) The Company announces that it has entered into an investor relations agreement (“Agreement”) with 551943 Alberta Ltd., operating as Colwell Capital Corp (“Colwell”), for a maximum term of twelve months commencing April 24, 2017. The Company will pay Colwell $4,000 per month and will… Read more »

  • biOasis Appoints Mark Day, Ph.D., as Chief Executive Officer and Director

    VANCOUVER, British Columbia–(Business Wire)– Bioasis Technologies, Inc. (OTCQB:BIOAF; TSX.V:BTI) (the “Company”) has appointed Mark Day, Ph.D., as President and Chief Executive Officer of the Company, effective immediately. Dr. Day succeeds Mr. Rob Hutchison who will become Executive Chairman of the Board of Directors of the Company. Dr. Day will also serve on the biOasis Board… Read more »

  • Mar. 31, 2017 biOasis Announces Oversubscription of Financing

    VANCOUVER, British Columbia–(Business Wire)– Bioasis Technologies, Inc. (OTCQB:BIOAF; TSX.V:BTI) (the “Company”) is pleased to announce that further to its press release dated March 20, 2017, the Company’s non-brokered private placement (the “Private Placement”), is currently over-subscribed. As a result, subject to regulatory approval, the size of the Private Placement has been increased from up to… Read more »

  • Mar. 20, 2017 biOasis Announces Non-Brokered Private Placement

    VANCOUVER, British Columbia–(Business Wire)– biOasis Technologies Inc. (TSX.V: BTI) (the “Company”) announces a nonbrokered private placement of up to 4,500,000 units at a price of $0.70 per unit of gross proceeds of up to $3,150,000 (the “Offering”). Each unit will consist of one common share and one-half common share purchase warrant. Each whole warrant entitles… Read more »

  • Jan. 23, 2017 biOasis Provides AGM Update – Expanding The biOasis Deal Flow Pipeline

    VANCOUVER, British Columbia–(Business Wire)– Bioasis Technologies, Inc. (OTCQB:BIOAF; TSX.V:BTI), a pioneering biopharmaceutical company focused on the delivery of therapeutic drugs across the blood-brain barrier (BBB), has provided a corporate update in advance of its Annual and Special Meeting of Shareholders to be held at 1780 – 400 Burrard Street, Vancouver, BC, on January 23, 2017… Read more »

  • Dec. 22, 2016 biOasis Announces Adoption of Restricted Share Unit Plan

    VANCOUVER, BC–(Business Wire)– Bioasis Technologies, Inc. (OTCQB:BIOAF; TSX.V:BTI) (the “Company”) announces that subject to approval by the TSX Venture Exchange (“TSXV”) and ratification by the Company’s shareholders at the 2016 Annual and Special General Meeting of shareholders (the “AGM”), the Company adopted a restricted share unit plan (the “RSU Plan”). Further details regarding the RSU… Read more »

  • Nov. 6, 2016 biOasis Attends BIO Europe and the Lockman BT2111 Paper is Honored by being Featured on the Cover of Pharmaceutical Research’s December Journal

    VANCOUVER, BC–(Business Wire)– Bioasis Technologies, Inc. (OTCQB:BIOAF; TSX.V:BTI), a pioneering biopharmaceutical company focused on overcoming the limitations of therapeutic drug delivery across the blood-brain barrier (BBB), today announced it’s team is attending BIO Europe, November 7th to 9th, in Cologne, Germany. In addition, the company announced that Dr. Paul Lockman’s recently published paper on biOasis’s… Read more »

  • Oct. 23, 2016 biOasis Engages Rising Tide Equity to Increase Global Awareness

    VANCOUVER, BC–(Business Wire)– Bioasis Technologies, Inc. (OTCQB:BIOAF; TSX.V:BTI), a pioneering biopharmaceutical company focused on overcoming the limitations of therapeutic drug delivery across the blood-brain barrier (BBB), today announced it has engaged Rising Tide Equity to increase its global awareness. Investors are increasingly using digital media and non-traditional media outlets to identify potential investment opportunities. Recent… Read more »